acut
myeloid
leukemia
aml
character
differenti
blockag
accumul
immatur
myeloid
cell
recogn
heterogen
disord
clinic
concept
differenti
therapi
consid
promis
approach
treatment
aml
sinc
success
use
alltransretino
acid
atra
acut
promyelocyt
leukemia
apl
elicit
complet
remiss
cr
apl
patient
brought
differenti
therapi
theoret
explor
clinic
applic
although
great
breakthrough
clinic
oncolog
achiev
differenti
therapi
atra
atrabas
therapi
show
poor
result
nonapl
aml
thu
tremend
effort
conduct
explor
novel
molecular
target
well
identifi
effici
differenti
compound
aml
treatment
offtarget
effect
tyrosin
kinas
inhibitor
tki
induc
aml
differenti
topic
consider
interest
last
year
imatinib
first
bcrabl
inhibitor
reveal
exert
unexpect
effect
potenti
atrainduc
aml
differenti
egfr
inhibitor
gefitinib
also
demonstr
enhanc
atrainduc
differenti
leukem
cell
trigger
differenti
aml
cell
line
lack
express
egfr
use
alon
dasatinib
target
varieti
tyrosin
kinas
notabl
bcrabl
fusion
protein
src
famili
kinas
sfk
use
treatment
bcrabl
cml
acut
lymphocyt
leukemia
imatinib
resist
intoler
previou
therapi
vitro
studi
shown
dasatinib
significantli
inhibit
growth
varieti
aml
cell
line
primari
blast
treat
alon
combin
cytotox
moleculartarget
agent
note
dasatinib
also
report
promot
atrainduc
differenti
aml
cell
line
restor
differenti
respons
nonapl
primari
aml
cell
atra
dasatinib
alon
could
promot
leukem
cell
differenti
contrast
lainey
et
al
studi
demonstr
dasatinib
could
overcom
amltyp
differenti
blockag
evidenc
dasatinibinduc
differenti
cell
effect
confirm
clinic
studi
provid
proof
prolong
differenti
myeloid
blast
bear
matur
dasatinib
treatment
inhibit
ckit
induct
caatenhanc
bind
demonstr
contribut
remark
responseinduc
dasatinib
howev
mechan
dasatinib
trigger
aml
differenti
remain
larg
unknown
present
studi
first
report
dasatinibinduc
differenti
aml
cell
accompani
activ
signal
transduc
activ
transcript
evidenc
augment
phosphoryl
redistribut
cytoplasm
nucleu
enhanc
transcript
direct
target
gene
show
knockdown
significantli
decreas
differenti
effect
dasatinib
indic
potenti
role
dasatinib
offtarget
effect
found
dasatinibinduc
activ
mekerk
cascad
depend
sinc
mek
inhibitor
inhibit
dasatinibtrigg
phosphoryl
also
abrog
dasatinibinduc
differenti
aml
cell
summari
result
suggest
novel
mechan
associ
differentiationinduct
effect
dasatinib
leukem
cell
may
provid
theoret
support
anticanc
approach
dasatinib
aml
human
acut
myeloid
leukemia
cell
cultur
rpmi
medium
plu
heatinactiv
fetal
bovin
serum
fb
human
embryon
kidney
cell
cultur
dulbecco
modifi
eagl
medium
plu
fb
cell
line
purchas
shanghai
institut
biochemistri
cell
biolog
shanghai
china
grown
medium
supplement
unitsml
penicillin
streptomycin
dasatinib
puriti
gener
gift
shanghai
institut
materia
medica
chines
academi
scienc
shanghai
china
nitroblu
tetrazolium
nbt
purchas
calbiochem
san
diego
ca
compound
dissolv
dmso
stock
experi
final
dmso
solvent
concentr
vv
cell
prolifer
viabil
assess
manual
count
use
standard
hemocytomet
follow
trypan
blue
stain
cell
cycl
distribut
determin
flow
cytometri
measur
dna
content
cell
incub
rnase
propidium
iodid
cellular
dna
content
analyz
facscalibur
flow
cytomet
use
cellquest
pro
softwar
bd
bioscienc
san
jose
ca
percentag
popul
measur
use
modfit
softwar
bd
bioscienc
least
cell
analyz
data
point
apoptosi
detect
fitc
annexin
v
apoptosi
detect
kit
accord
manufactur
instruct
bd
bioscienc
determin
phosphatidyl
serin
exposur
apoptot
cell
quantifi
facscalibur
flow
cytomet
use
cellquest
pro
softwar
least
cell
analyz
data
point
fluorochrom
conjug
monoclon
antibodi
use
detect
express
follow
protocol
manufactur
bd
bioscienc
stain
cell
run
facscalibur
flow
cytomet
quanitit
use
cellquest
pro
softwar
least
cell
analyz
data
point
cell
stain
mous
iggp
serv
neg
control
nbt
reduct
morpholog
analysi
cytospin
prepar
made
use
shandon
cytospin
cytocentrifug
nbt
reduct
perform
examin
cell
contain
precipit
formazan
particl
describ
least
cell
assess
experi
cell
morpholog
evalu
stain
examin
leica
microscop
captur
leica
fx
chargecoupl
devic
camera
cell
treat
dasatinib
vehicl
collect
cytospin
onto
slide
fix
paraformaldehyd
room
temperatur
cell
permeabil
triton
min
wash
pb
block
fb
min
cell
stain
indic
primari
santa
cruze
ca
overnight
follow
alexa
fluor
second
antibodi
life
technolog
corp
eugen
dapi
h
room
temperatur
incub
step
follow
three
wash
pb
imag
stain
cell
obtain
leica
fluoresc
microscop
leica
fx
chargecoupl
devic
camera
total
rna
isol
cell
treat
dasatinib
vehicl
use
trizol
reagent
bio
basic
inc
markham
ontario
canada
rna
transcrib
cdna
use
random
hexam
primer
revertaidtm
mmulv
revers
transcriptas
fermenta
intern
inc
burlington
ontario
canada
equilibr
amount
cdna
taken
transcript
pcr
amplif
perform
use
sybr
premix
ex
taq
takara
biotechnolog
dalian
china
housekeep
gene
gapdh
use
intern
standard
primer
sequenc
use
pcr
follow
rigg
forward
revers
forward
revers
gapdh
forward
revers
pcr
protocol
consist
thermal
cycl
follow
initi
denatur
min
follow
cycl
use
eppendorf
epgradi
mastercycl
eppendorf
hamburg
germani
experi
two
neg
control
carri
step
data
quantit
perform
use
rel
standard
curv
method
protein
extract
separ
sdspage
electroblot
onto
pvdf
membran
accord
standard
procedur
membran
block
nonfat
dri
milk
incub
respect
primari
antibodi
akt
pakt
cmyc
erk
jnk
mek
gapdh
obtain
santa
cruz
biotechnolog
inc
santa
cruz
ca
well
perk
pjnk
pmek
purchas
cell
signal
technolog
danver
western
blot
visual
hrpconjug
secondari
antibodi
jackson
immunoresearch
laboratori
inc
west
grove
pa
follow
enhanc
chemiluminesc
detect
biolog
industri
beit
haemek
israel
human
lentivir
shrna
set
includ
clone
empti
lentivir
vector
purchas
open
biosystem
nontarget
shrna
control
plasmid
purchas
sigma
infecti
lentiviru
produc
cotransfect
cell
shrnaexpress
lentivir
plasmid
togeth
packag
plasmid
envelop
plasmid
pmdg
supernat
contain
infecti
viru
particl
collect
h
transfect
use
transduc
cell
spinocul
presenc
polybren
posit
transduct
select
puromycin
express
analyz
western
blot
statist
signific
differ
group
evalu
unpair
student
test
indic
p
p
p
statist
test
twosid
exponenti
grow
cell
treat
differ
concentr
dasatinib
indic
exposur
time
compar
control
group
dasatinib
significantli
inhibit
prolifer
cell
dose
timedepend
manner
fig
interestingli
found
dasatinib
exhibit
littl
effect
viabil
cell
except
high
concentr
apoptosi
cell
observ
fig
data
shown
explor
antineoplast
effect
dasatinib
within
concentr
studi
effect
trigger
cell
differenti
cell
cycl
arrest
h
treatment
fig
shown
fig
dasatinib
induc
express
myeloid
differenti
marker
dosedepend
manner
consist
previou
studi
dasatinibinduc
differenti
parallel
phase
arrest
fig
studi
progress
dasatinibinduc
differenti
cell
treat
dasatinib
h
note
dasatinibinduc
express
alreadi
detect
earli
h
albeit
slightli
approxim
posit
cell
popul
increas
h
h
respect
fig
even
reach
day
data
shown
moreov
dasatinibinduc
phase
arrest
also
line
differenti
progress
detect
h
treatment
fig
consist
dasatinib
significantli
decreas
express
cmyc
involv
leukem
cell
prolifer
increas
express
play
import
role
prevent
cell
cycl
progress
fig
differentiationinduc
capac
dasatinib
determin
anoth
aml
cell
line
cell
dasatinibinduc
express
dosedepend
manner
low
concentr
howev
high
concentr
dasatinib
induc
enhanc
express
fig
could
attribut
dasatinibinduc
increas
hypodiploid
cell
h
upon
high
concentr
dasatinib
treatment
approxim
cell
accumul
sub
phase
actual
dasatinibinduc
cellcycl
blockad
manifest
accumul
sub
phase
cell
obviou
phase
arrest
alreadi
detect
h
dasatinib
treatment
hypodiploid
cell
observ
fig
furthermor
abil
dasatinib
induc
aml
differenti
also
confirm
morpholog
chang
cell
name
reduct
nucleu
cytoplasm
ratio
obviou
nuclear
segment
compar
control
group
fig
taken
togeth
result
indic
dasatinib
exert
differenti
effect
aml
cell
numer
report
demonstr
essenti
role
stat
protein
myeloid
differenti
intend
determin
whether
dasatinibinduc
aml
differenti
mediat
stat
signal
pathway
cell
incub
dasatinib
indic
time
analyz
phosphoryl
stat
protein
shown
fig
dasatinib
treatment
led
increas
phosphoryl
within
h
augment
time
wherea
dasatinib
significantli
decreas
phosphoryl
almost
undetect
h
treatment
addit
dasatinb
exhibit
littl
effect
phosphoryl
fig
data
shown
given
phosphoryl
transloc
nucleu
exert
gene
regul
effect
determin
local
immunofluoresc
assay
absenc
dasatinib
predominantli
cytoplasm
dasatinib
treatment
induc
redistribut
cytoplasm
nucleu
fig
confirm
abil
phosphoryl
gene
transcript
regul
express
two
direct
target
gene
rigg
test
real
time
pcr
shown
fig
transcript
gene
enhanc
dasatinib
timedepend
manner
consist
result
dasatinibinduc
activ
also
observ
cell
modest
increas
virtual
detect
h
dasatinib
treatment
level
return
baselin
h
level
return
baselin
h
fig
result
indic
might
play
role
dasatinibinduc
differenti
aml
cell
find
significantli
activ
aml
cell
dasatinib
treatment
prompt
us
investig
whether
contribut
dasatinibinduc
differenti
endogen
express
knock
shrna
shrna
clone
two
shrna
sequenc
exhibit
strongest
knockdown
effici
select
silenc
express
cell
shown
fig
express
significantli
reduc
express
cell
compar
vector
nontarget
shrna
expect
silenc
express
significantli
inhibit
dasatinibinduc
aml
differenti
detail
cell
show
markedli
reduc
nbt
posit
cell
dasatinib
treatment
compar
vector
nontarget
shrnaexpress
cell
vector
nontarget
shrna
respect
fig
cell
also
demonstr
significantli
reduc
express
dasatinib
treatment
compar
vector
nontarget
shrnaexpress
cell
vector
nontarget
shrna
respect
fig
moreov
shrnatransduc
cell
exhibit
less
matur
granulocyt
morpholog
compar
vector
nontarget
shrnatransduc
cell
evidenc
decreas
ratio
cytoplasm
nuclear
fig
result
indic
knockdown
cell
result
significantli
decreas
differenti
respons
dasatinib
stimul
given
phosphoryl
tyrosin
janu
kinas
jak
famili
member
serin
mapk
cascad
includ
mek
erk
jnk
well
pathway
first
evalu
effect
dasatinib
kinas
unexpectedli
dasatinib
effect
phosphoryl
data
shown
addit
neither
dasatinibinduc
express
dasatinibenhanc
phosphoryl
affect
jak
inhibitor
fig
contrast
phosphoryl
mek
augment
within
h
increas
high
level
h
dasatinib
treatment
fig
consist
enhanc
phosphoryl
erk
also
detect
earli
h
maintain
high
level
least
h
determin
effect
dasatinib
phosphoryl
mapk
famili
member
jnk
shown
fig
phosphoryl
transient
abolish
within
h
return
baselin
h
dasatinib
treatment
dasatinib
exhibit
littl
effect
phosphoryl
jnk
akt
determin
whether
phosphoryl
mekerk
cascad
indispens
dasatinibinduc
aml
differenti
cell
treat
dasatinib
presenc
mek
inhibitor
analyz
express
concentr
treat
respect
cytotox
observ
cell
line
treat
alon
combin
dasatinib
data
shown
shown
fig
significantli
inhibit
dasatinibinduc
express
cell
detail
popul
cell
decreas
cell
cell
presenc
respect
addit
also
significantli
inhibit
dasatinibinduc
phase
arrest
especi
cell
percentag
phase
cell
decreas
fig
expect
activ
mek
erk
success
inhibit
fig
interestingli
phosphoryl
site
strikingli
inhibit
cell
result
corrobor
anoth
mek
inhibitor
dasatinibinduc
express
decreas
presenc
fig
western
blot
analysi
also
confirm
inhibit
dasatinibinduc
serin
phosphoryl
also
abrog
tyrosin
phosphoryl
fig
taken
togeth
dasatinibinduc
activ
depend
mekerk
activ
thu
lead
differenti
leukem
cell
present
studi
demonstr
capac
dasatinib
induc
leukem
cell
differenti
evidenc
enhanc
express
phase
arrest
decreas
ratio
nuclear
cytoplasm
dasatinibtr
aml
cell
notabl
found
biolog
function
dasatinib
induc
aml
differenti
mediat
mekerk
depend
activ
stat
famili
protein
activ
cytokin
hormon
growth
factor
function
transcript
factor
mediat
varieti
biolog
process
cell
prolifer
apoptosi
among
least
seven
member
report
play
essenti
role
myeloid
differenti
activ
first
identifi
atrainduc
myeloid
differenti
variou
leukemia
cell
line
addit
also
report
activ
bryostatin
mediat
differenti
chronic
lymhocyt
leukemia
cell
cll
observ
signific
increas
tyrosin
serin
phosphoryl
dasatinib
treatment
accompani
transloc
cytoplasm
nucleu
thu
lead
enhanc
transcript
target
gene
silenc
express
shrna
significantli
lessen
dasatinibinduc
differenti
suggest
essenti
role
dasatinib
differenti
effect
addit
phenomenon
phosphoryl
return
basal
level
even
lower
cell
late
time
dasatinib
treatment
might
result
intracellular
signal
trigger
apoptosi
cell
contrast
tumor
suppressor
function
activ
mainli
identifi
oncogen
constitut
tyrosin
serin
phosphoryl
demonstr
mani
differ
malign
includ
aml
inhibit
activ
induc
apoptosi
aml
cell
line
primari
sampl
howev
import
role
granulocyt
differenti
also
report
vitro
vivo
studi
thu
exact
role
leukemogenesi
remain
controversi
studi
tyrosin
phosphoryl
significantli
downregul
dasatinib
serin
phosphoryl
unaffect
previou
studi
demonstr
constitut
phosphoryl
serin
tyrosin
requir
dnabind
transcript
activ
target
gene
surviv
thu
serin
phosphoryl
might
disrupt
apoptot
signal
pathway
caus
decreas
tyrosin
phosphoryl
therebi
confer
surviv
advantag
necessari
differenti
cell
report
directli
phosphoryl
protein
tyrosin
site
follow
activ
ifn
receptor
respect
ligand
seem
potenti
target
dasatinib
detail
dasatinib
caus
chang
level
phosphoryl
neither
dasatinibinduc
express
dasatinibenhanc
phosphoryl
affect
jak
inhibitor
previou
studi
shown
phosphoryl
serin
site
sever
kinas
includ
mek
erk
jnk
kinas
pathway
found
mek
erk
significantli
activ
dasatinib
treat
aml
cell
howev
phosphoryl
total
abrog
dasatinib
except
recoveri
h
phosphoryl
jnk
akt
hardli
chang
dasatinib
treatment
extend
observ
show
activ
mekerk
cascad
indispens
dasatinib
differenti
effect
critic
show
dasatinibinduc
express
arrest
significantli
inhibit
mek
inhibitor
line
fact
dasatinibinduc
phosphoryl
tyrosin
serin
site
inhibit
mek
inhibitor
indic
mekerkdepend
activ
might
indispens
differenti
effect
dasatinib
sfk
report
activ
rasrafmekerk
pathway
via
recruit
shc
protein
observ
dasatinib
effici
sfk
inhibitor
inhibit
mekerk
cascad
aml
cell
contrari
dasatinib
significantli
induc
phosphoryl
mek
erk
approv
indispens
dasatinib
differenti
effect
phenomenon
could
partial
explain
fact
dasatinib
also
weak
raf
inhibitor
packer
et
al
report
bind
weak
raf
inhibitor
imatinib
nilotinib
dasatinib
braf
craf
drive
braf
craf
heterodim
well
brcf
craf
homodim
format
presenc
oncogenet
ra
thu
lead
paradox
activ
braf
craf
follow
activ
mek
erk
consid
complex
mechan
involv
activ
rasrafmekerk
pathway
studi
perform
better
understand
effect
dasatinibinduc
activ
mekerk
kinas
futur
work
summari
present
result
demonstr
first
time
differentiationinduct
effect
dasatinib
requir
activ
depend
mekerk
cascad
activ
result
suggest
attempt
treat
aml
combin
dasatinib
mek
inhibitor
made
great
caution
identif
potenti
molecular
mechan
dasatinib
biolog
effect
aml
differenti
may
provid
molecular
theoret
basi
clinic
applic
dasatinib
combin
target
base
drug
leukemia
therapi
